Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis.
Karina Rossi BonfiglioliLicia Maria Henrique da MotaAna Cristina de Medeiros RibeiroAdriana Maria KakehasiIeda Maria Magalhães LaurindoRina Dalva Neubarth GiorgiAngela Luzia Branco Pinto DuarteAna Paula Monteiro Gomides ReisMariana Peixoto Guimarães Ubirajara E Silva de SouzaClaiton Viegas BrenolGeraldo da Rocha Castelar PinheiroCleandro Pires de AlbuquerqueCharlles Heldan de Moura CastroGustavo Luiz Behrens PintoJose Fernando VerztmanLuciana Feitosa MunizManoel Barros BertoloMaria Raquel da Costa PintoPaulo Louzada JúniorVitor Alves CruzIvanio Alves PereiraMax Vitor Carioca de FreitasBóris Afonso CruzEduardo PaivaOdirlei MonticieloJosé Roberto ProvenzaRicardo Machado XavierPublished in: Advances in rheumatology (London, England) (2021)
Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.
Keyphrases
- rheumatoid arthritis
- disease activity
- systemic lupus erythematosus
- ankylosing spondylitis
- rheumatoid arthritis patients
- end stage renal disease
- juvenile idiopathic arthritis
- ejection fraction
- interstitial lung disease
- chronic kidney disease
- newly diagnosed
- multiple sclerosis
- machine learning
- clinical practice
- combination therapy
- peritoneal dialysis